Amylyx Pharmaceuticals, Inc. (AMLX) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Amylyx Pharmaceuticals, Inc.

AMLX

NASDAQ

Unprofitable

332M

Biotechnology

Next Earning date - 08 May 2025

332M

Biotechnology

Next Earning date - 08 May 2025

3.75USD

0.13 ( 3.45%)

Market Closed (as of Mar 17, 20:00 EDT)

Relative Strenght

Volume Buzz

-52%

Earning Acce

Dist 52w H.

48%

Overview Chart

Quote Panel

Updated March 18, 2025

1W -4.09 % 1M 6.53 % 3M -5.30 % 1Y 27.99 %

Key Metrics

Market Cap
332.26M
Shares Outstanding
88.60M
Share in Float
63.80M
Dividende
0

Earning Date
08 May 2025
Price Target
3.75
Average Volume
850381
Beta
-0.506

Range
1.575-7.27
Industry
Biotechnology
Website
https://amylyx.com
Sector
Healthcare

Quote Panel

Updated March 18, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

3.68x

P/S Ratio

1.51x

P/B Ratio

0.0

Debt/Equity

-345.4%

Net Margin

$-4.4

EPS

How AMLX compares to sector?

P/E Ratio

Fundamentals

Relative Strength

AMLX

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

AMLX

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$115M

17323%

2025-Revenue

$2.01

-265%

2025-EPS

$89M

-120%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

0.00(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Bank of America Securities

upgrade

Previous: Not converted

2024-10-23

Now: Buy

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q1.23

+102%

0.02
vs -0.93

Q2.23

+133%

0.31
vs -0.93

Q3.23

+133%

0.3
vs -0.92

Q4.23

+111%

0.07
vs -0.65

Q1.24

N/A

-0.46
vs 0.02

Q2.24

N/A

-0.73
vs 0.31

Q3.24

N/A

-0.53
vs 0.3

Q4.24

N/A

-0.55
vs 0.07

Q1.25

N/A

-0.50
vs -0.46

Q2.25

N/A

-0.50
vs -0.73

Sales Growth

YoY

Current

Estimates

Q1.23

71.4M vs NA

Q2.23

98.2M vs NA

Q3.23

+29666%

102.7M vs 345K

Q4.23

+396%

108.4M vs 21.9M

Q1.24

+24%

88.6M vs 71.4M

Q2.24

-101%

-1022999.00 vs 98.2M

Q3.24

-100%

416K vs 102.7M

Q4.24

-101%

-665000.00 vs 108.4M

Q1.25

-34%

58.1M vs 88.6M

Q2.25

+5225%

52.4M vs -1022999

Return on Equity

QoQ

Q1.23

+0%

0
vs -0.13

Q2.23

+6%

0.06
vs 0

Q3.23

+5%

0.05
vs 0.06

Q4.23

+1%

0.01
vs 0.05

Q1.24

-37%

-0.37
vs 0.01

Q2.24

-28%

-0.28
vs -0.37

Q3.24

-37%

-0.37
vs -0.28

Q4.24

-23%

-0.23
vs -0.37

Institutionnal Ownership

QoQ

Q1.23

164

164
vs 149

10%

Q2.23

170

170
vs 164

Q3.23

189

189
vs 170

11%

Q4.23

206

206
vs 189

Q1.24

177

177
vs 206

-14%

Q2.24

128

128
vs 177

-28%

Q3.24

116

116
vs 128

-9%

Q4.24

131

131
vs 116

13%

Earnings Growth

Latest News

accessnewswire.com

10 hours ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation

accessnewswire.com

10 hours ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation

accessnewswire.com

10 hours ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation

accessnewswire.com

10 hours ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out

accessnewswire.com

10 hours ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out

seekingalpha.com

12 hours ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2024 Earnings Call Transcript

Company Description

3.75USD

N/A

3.68x

1.51x

0.0

-345.4%

$-4.4

$115M

$2.01

$89M

Earnings Growth

Latest News

Latest News

$115M

$2.01

$89M

Latest News

N/A

3.68x

1.51x

0.0

-345.4%

$-4.4